Walleye Trading’s Accelerate Diagnostics AXDX Stock Holding History

Walleye Trading’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-274	Closed	-$23K	–	4225
2020 Q1	$23K	Buy	+274	New	+$38.6K	﹤0.01%	3607

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

GAM

Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Walleye Trading's AXDX Position: Q2 2020 in Review

Walleye Trading sold out of Accelerate Diagnostics (AXDX) in Q2 2020, closing a stake of 274 shares — an estimated $23K sold.

Walleye Trading first reported a position in AXDX in Q1 2020 and held it in 1 quarter. The position peaked at $23K in Q1 2020. 123 funds tracked by Wall St. Rank hold AXDX as of Q2 2020.

Walleye Trading reported no remaining Accelerate Diagnostics position as of Q2 2020 after selling out during the quarter.
Walleye Trading sold 274 Accelerate Diagnostics shares in Q2 2020, an estimated $23K.
Walleye Trading first reported a position in Accelerate Diagnostics in Q1 2020 and held it in 1 quarter.
Walleye Trading's Accelerate Diagnostics position peaked at $23K in Q1 2020.
123 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2020.

Based on Walleye Trading's 13F filing for Q2 2020, filed 14 Aug 2020.